CTOS Nurse and Allied Health Professionals Conference

Pediatric Sarcomas and Rare Sarcomas in Adults

Chairmen: L. Helman, Pediatric Oncology Branch, NCI, Bethesda, MD, USA
P. Meyers, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

[Abstract 397] PHOSPHORYLATION PROFILE OF TYROSINE KINASES AND AKT/MTOR PATHWAYS IN RHABDOMYOSARCOMA.
Ling Cen¹, Kristy Arnoczky¹, Fu-Chuan Hsieh¹, Huey-Jen Lin¹, Stephen J. Qualman¹, Jiayuh Lin¹

[Abstract 425] EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model.
Patrick P Lin¹, Fenghua Jin¹, Carolyn Van Pelt¹, Guillermina Lozano¹

[Abstract 393] PET AFTER CHEMOTHERAPY IN RHABDOMYOSARCOMA
Michelle L Klem¹, Leonard H Wexler¹, Ravinder Grewal¹, Heiko Schoder¹, Paul A Meyers¹, Suzanne L Wolden¹

Fascinoma in CTOS Abstracts: a Review
R. Maki, New York

Pathological and Molecular Diagnosis of Sarcomas

Chair: P. Picci Istituto Rizzoli, Bologna, Italy and C.Corless OHSU, Portland, OR, USA

[Abstract 410] EXPRESSION OF GROUCHO/TRANSDUCIN-LIKE ENHANCER OF SPLIT PROTEIN DISTINGUISHES SYNOVIAL SARCOMA FROM MALIGNANT PERIPHERAL NERVE SHEATH TUMOR.
Torsten Nielsen¹, Brian Rubin², Cindy Ruttan¹, Suzanne Liu¹, Matt van de Rijn³

[Abstract 438] MUTATIONAL ANALYSIS OF EXT1 AND EXT2 GENES AND A NEW SYSTEM FOR “GRADING” CLINICAL EXPRESSION OF DISEASE IN PATIENTS WITH HEREDITARY MULTIPLE EXOSTOSES
Luca Sangiorgi¹, Nicola Fabbri¹, Laura Campanacci¹, Elena Pedrini¹, Veronica Maini¹, Silvia Capponcelli¹, Marina Mordenti¹, Piero Picci¹, Mario Mercuri¹

[Abstract 441] ESTROGEN RECEPTOR-BETA EXPRESSION IN EXTRA-ABDOMINAL DESMOID TUMORS
Andrea T. Deyrup¹, Maria Tretiakova², Anthony G. Montag²

[Abstract 383] PROTEOMIC SIGNATURE OF SOFT-TISSUE TUMORS CORRESPONDING TO HISTOLOGICAL CLASSIFICATION AND GRADING.
Yoshiyuki Suehara¹, Tadashi Kondo¹, Akira Kawai², Tadashi Hasegawa⁴, Kiyonaga Fujii³, Toshihide Nishimura³, Yasuo Beppu², Setsuo Hirohashi¹

[Abstract 389] EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR, ERBB2, AND KIT IN ADULT SOFT TISSUE SARCOMAS: A CLINICOPATHOLOGICAL STUDY OF 281 CASES
Takuro Wada¹, Osamu Sato¹, Akira Kawai², Atsushi Makimoto², Toshihiko Yamashita¹, Tadashi Hasegawa²

[Abstract 424] ERBB1-B4, NA17 AND MAGE GENE EXPRESSION ANALYSIS IN 77 SOFT TISSUE AND BONE TUMORS.
Sophie Piperno-Neumann¹, Patricia de Cremoux¹, Gonzague de Pinieux², Philippe Anract², Delphine Robert¹, Carine Tran-Perennou¹, Antoine Babinet², Valerie Laurence¹, Bernard Tomeno², Pierre Pouillart¹, Olivier Lantz¹

General discussion: Molecular Biology : A Research Tool or a Need for Routine Management of Sarcomas?

CTOS General Session
Initial management and surgery

Chair: A. Gronchi Instituto Tumori, Milano, Italy and R. Grimer Royal Orthopaedic Hospital, Northfield, Birmingham, UK

[Abstract 453] A EUROPEAN PROJECT FOR SURGICAL MARGINS ASSESSMENT IN SOFT TISSUE SARCOMA OF THE EXTREMITIES AND SUPERFICIAL TRUNK.
Alessandro Gronchi¹, Robert J. Grimer², Pancras C.W. Hogendoorn³, Frits Van Coevorden⁴, Henrik Bauer⁵, Lars-Gunnar Kindblom^1,2, Sylvie Bonvalot⁶, Jean Michel Coindre⁷, Peter Hohenberger⁸, Eva Wardelmann⁹, Wlodzimierz Ruka¹⁰, Piotr Rutkowski¹⁰, Paola Collini¹, Luigi Mariani¹, Angelo Paolo Dei Tos¹¹

[Abstract 413] WHAT’S THE SIGNIFICANCE OF A MARGINAL MARGIN?
Robert John Grimer¹

[Abstract 481] THE SURGICAL MANAGEMENT OF SACRAL TUMORS
Wei Guo¹, Wanpeng Xu¹, Rongli Yang¹, Xiaodong Tang¹

[Abstract 395] CHONDROSARCOMA OF THE PELVIS: PROGNOSTIC FACTORS AND SURVIVAL ANALYSIS AT 10-20 YEARS
Matthew J Seidel, MD¹, Patrick P Lin, MD¹, Valerae O Lewis, MD¹, Christopher P Cannon, MD¹, Alan W Yasko, MD¹

[Abstract 456] CLINICOPATHOLOGIC FEATURES OF DIAPHYSEAL OSTEOSARCOMA
Anne Nicole Normand¹, Patrick P Lin¹, Christopher P Cannon¹, Valerae O Lewis¹, Alan W Yasko¹

[Abstract 473] ADAMANTINOMA OF THE LONG BONES: CLINICOPATHOLOGICAL STUDY WITH EMPHASIS ON IMAGING, (IMMUNO)HISTOPATHOLOGY, AND SURGICAL TREATMENT.
Antonie Taminiau¹

Discussion: Optimal Margins?

Surgery in advanced phase: why? when? to whom?

Chair: K. Weber Johns Hopkins School of Medicine Baltimore, MD, USA and P. Hohenberger, Chirurgische Universitatsklinik Mannheim.Deutschland

[Abstract 459] SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST) FOLLOWING TREATMENT WITH KIT-DIRECTED CHEMOTHERAPY
Chandrajit P Raut¹, Matthew Posner¹, Jayesh Desai², George D Demetri², Jeffrey A Morgan², Suzanne George², David Zahrieh², Christopher DM Fletcher¹, Monica M Bertagnolli¹

[Abstract 399] ADVANCED GASTRO-INTESTINAL STROMAL TUMOR: MOLECULAR, PATHOLOGICAL AND CLINICAL PATTERN IN POST-IMATINIB SURGERY.
Alessandro Gronchi¹, Marco Fiore¹, Rossella Bertulli¹, Elena Tamborini¹, Paola Collini¹, Silvana Pilotti¹, Chiara Mussi¹, Paola Coco¹, Antonella Messina¹, Silvia Stacchiotti¹, Paolo Giovanni Casali¹

[Abstract 444] OUTCOME FOLLOWING LOCAL RECURRENCE OF SOFT TISSUE SARCOMA
Naomi Slator¹, Rob Grimer¹, Simon Carter¹, Roger Tillman¹, Seggy Abudo¹

[Abstract 466] PULMONARY METASTASES FROM OSTEOSARCOMA: MULTIFACTORIAL ANALYSIS OF SURVIVAL
Ali Aljubran¹, Martin Blackstein¹

[Abstract 465] CT GUIDED RADIOFREQUENCY ABLATION IN 24 PATIENTS WITH SPINAL OSTEOID OSTEOMAS
Sander Dijkstra¹, Wim Obermann², Antoni Taminiau¹

Discussion: Surgery of Relapses and Metastasis: When? to Whom?

CTOS Special Lecture: Hermann Suit

Presentation by the chairman of CTOS

Title of the Hermann Suit presentation: TBD, example CTOS 1993-2005: why do we need more than ever an international society on sarcomas

Lunch & Poster Viewing

CTOS Board of Director Meeting

Radiotherapy

Chair: M. Robinson, Weston Park Hospital NHS Trust, United Kingdom and T. Delaney, Massachusetts General Hospital, Harvard Medical School, Boston, USA.

[Abstract 504] A RADIATION TREATMENT PLANNING COMPARISON FOR LOWER EXTREMITY SOFT TISSUE SARCOMA: CAN THE FUTURE SURGICAL WOUND BE SPARED?
Anthony M. Griffin¹, Colleen I Euler², Michael B. Sharpe², Jay S Wunder¹, Peter C Ferguson¹, Robert S Bell¹, Charles N. Catton³, Peter W. Chung³, O’Sullivan Brian3

[Abstract 495] DETERMINATION OF THE POTENTIAL INDICATIONS OF HADRONTHÉRAPIE IN THE SARCOMAS STARTING FROM AN ANALYSIS OF THE LITERATURE.
Marie-Pierre Sunyach¹, Emmanuel Amselem¹, Pascal Pommier¹, Jean-Yves Blay¹

[Abstract 411] PROTON RADIOTHERAPY FOR TREATMENT OF SARCOMAS OF THE SPINE AND PARASPINAL TISSUES
Thomas F. DeLaney¹, Norbert J. Liebsch¹, Ira J. Spiro¹, Patricia L. McManus¹, Judith Adams¹, Susan Dean¹, Francis J. Hornicek², Francis X. Pedlow⁶, Andrew L. Rosenberg³, G. Petur Nielsen³, David C. Harmon⁴, Sam S. Yoon⁵, Kevin A. Raskin², Herman D. Suit¹

Young Investigator Award Winner
[Abstract 464] HIT OR MISS: IS THERE A ROLE FOR CT/MRI FUSION IN SARCOMA RADIOTHERAPY PLANNING?
Paris-Ann Gfeller¹, Charlie Candish¹, Lorna Weir¹, Clive Grafton¹, Carol Marlowe¹, Ciaran Keogh¹, Karen Goddard¹

Discussion: New Strategies for Radiotherapy in Sarcoma?

Cytotoxic Chemotherapy and Targeted Therapies

Chair: L. Baker University of Michigan Cancer Center, Ann Arbor, MI, USA and A. Le Cesne Institut G. Roussy, Villejuif, France

[Abstract 447] UPDATED INTERIM RESULTS OF A PHASE 2 STUDY OF THE MTOR INHIBITOR AP23573 IN PATIENTS (PTS) WITH ADVANCED SARCOMAS OF SOFT TISSUE OR BONE
Sant P Chawla¹, Anthony W Tolcher², Kamalesh K Sankhala¹, Arthur P Staddon3, Camille L Bedrosian⁴, George D Demetri⁵

[Abstract 437] A SARC MULTICENTER PHASE III STUDY OF GEMCITABINE (G) VS. GEMCITABINE AND DOCETAXEL (G+D) IN PATIENTS WITH METASTATIC SOFT-TISSUE SARCOMAS (STS).
Robert G. Maki¹, J. Kyle Wathen², Shreyaskumar R. Patel², Dennis A. Priebat³, Scott Okuno⁴, Brian L. Samuels⁵, David C. Harmon⁶, Peter F. Thall², Robert S. Benjamin², Laurence H. Baker⁷

[Abstract 391] DOCETAXEL AND GEMCITABINE ASSOCIATION IN 113 ADVANCED SOFT TISSUS SARCOMAS: A RETROSPECTIVE ANALYSIS.
BAY Jacques-Olivier¹, FAYETTE Jerome², PIPERNO-NEUMANN Sophie³, CHEVREAU Christine⁴, ISAMBERT Nicolas⁵, BRAIN Etienne⁶, EMILE Georges⁶, PENEL Nicolas⁷, PEYRADE Frédéric8, KERBRAT Pierre⁹, GUILLEMET Cécile¹⁰, RAY-COQUARD Isabelle², BLAY Jean-Yves²

[Abstract 446] A DEFICIENT HOMOLOGOUS RECOMBINATION DNA REPAIR (HRR) APPEARS TO CLUSTER SARCOMA (SAR) PATIENTS (PTS) SENSITIVE (S) TO YONDELIS (ET-743, TRABECTEDIN).
Robert Maki¹, Miquel Taron², Allan Van Oosterom³, Patrick Schoffski³, Juan C. Tercero⁴, Jose M. Fernandez Sousa-Faro⁴, Jose M. Jimeno⁴, Rafael Rosell²

[Abstract 432] SAFETY OF CAELYX COMBINED WITH IFOSFAMIDE IN PREVIOUSLY UNTREATED ADULT PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUES SARCOMAS (STS). FINAL DATA OF AN EORTC PHASE 1 STUDY.
Ole Steen Nielsen¹, Peter Reichardt², Daniel Pink², Jacob Lindegaard¹, Catherine Hermans⁴, Konstantin Stoichkov⁴, Ian Judson⁵, Soren Daargard¹

[Abstract 439] NON METASTATIC EWING'S FAMILY TUMORS: HIGH DOSE CHEMOTHERAPY WITH PERIPHERAL BLOOD STEM CELL RESCUE IN POOR RESPONDER PATIENTS: PRELIMINARY RESULTS OF ISG/SSG III PROTOCOL
Stefano Ferrari¹, Amelia Tienghi¹¹, Mario Mercuri¹, Franco Bertoni¹, Enza Barbieri², Franca Fossati Bellani³, Roberto Luksch³, Gabriella Bernini⁴, Adalberto Brach del Prever⁵, Franca Fagioli⁵, Piero Picci¹, Gaetano Bacci¹, Sigbjorn Smeland⁶, Tom Bohling⁷, Otte Brosjo⁹, Gunnar Saeter⁶, Thomas Wiebe⁸, Thor Alvegard¹⁰

Cytotoxic and Targeted Therapies on Sarcomas and GIST

Chair: G. Demetri DanaFarber Cancer Institute, Boston, MA, USA and P. Casali Istituto dei Tumori, Milano, Italy

Young Investigator Award Winner
[Abstract 457] TARGETING HSP90 IN IM-RESISTANT GIST: KIT DEGRADATION AS A BROADLY RELEVANT SALVAGE STRATEGY.
Sebastian Bauer¹, Lynn Yu¹, George D Demetri², Jonathan A Fletcher¹

[Abstract 371] CHARACTERIZATION OF SOMATOSTATIN TYPE 2 RECEPTOR EXPRESSION IN BONE AND SOFT TISSUE SARCOMAS
William Ahrens¹, Matthew DiCaprio¹, David Magit¹, Gina Chung¹, Runar Kellogg¹, Dieter Lindskog¹, Irvin Modlin¹, Gary Friedlaender¹, John Murren¹

[Abstract 364] PHASE I VACCINATION TRIAL OF SYT-SSX JUNCTION PEPTIDE AND ITS HLA-A*2402 ANCHOR SUBSTITUTE IN PATIENTS WITH DISSEMINATED SYNOVIAL SARCOMA
Satoshi Kawaguchi¹, Takuro Wada¹, Satoshi Nagoya¹, Yuriko Sato¹, Kazunori Ida¹, Toshihiko Torigoe¹, Noriyuki Sato¹, Takeshi Ishii², Shin-ichiro Tatezaki², Toshihiko Yamashita¹

Abstract 490 ABT526 and ABT510, ANTIANGIOGENIC THROMBOSPONDIN-1 PEPTIDES, ARE ACTIVE IN DOGS WITH NATURALLY OCCURRING CANINE CANCERS INCLUDING SOFT TISSUE SARCOMAS.
Anthony Rusk¹, Jack Henkin², Anthony Rusk¹, Fortuna Haviv², Sandra Majest², Chand Khanna¹

Abstract 487 IS PROGRESSION FREE SURVIVAL (PFS) IN PHASE II STUDIES A CLINICALLY USEFUL SURROGATE?
Laurence H Baker¹, Scott Schuetze¹, Rashmi Chugh¹

Discussion: New agents for the Treatment of Sarcomas

The Five Minute Presentation of Each Group and Prospective for Collaborations

Chair: I.Judson Royal Marsden London UK and R. Maki Memorial Sloane Kettering New York, NY

ICAS, SARC, EORTC, ISG, FSG, SSG, MRC, ACOSOG, GEIS, RTOG

Coffee Break and Poster Viewing

Nina Axelrad Lecture: M. Van Glabbeke (EORTC, Brussel, Belgium)

Chair: V. Bramwell University Hospital Calgary, Canada and R. Benjamin MDACC Houston, TX, USA

Clinical Trials in Sarcoma : What We Did, What We Will Do?
M. Van Glabbeke EORTC, Brussel, Belgium

Special Session: Clinical Practice Guidelines

Chair: S. Patel MDACC Houston, TX, USA and JY Blay Lyon, France

Clinical Practice Guidelines in Bone Sarcoma in the US
L. Randall

Clinical Practice Guidelines in Sarcoma in Canada
V. Bramwell

French Guidelines (SOR): Any Impact Since 1995
BN Bui

Clinical Practice Guidelines in Sarcoma in Germany
P. Hohenberger

Clinical Practice Guidelines in Scandinavia
K. Sundby Hall

[Abstract 436] EVIDENCE BASED GUIDELINES FOR PROVISION OF SARCOMA SERVICES
R. Grimer et al, Birmingham

Toward Common Guidelines in European Groups
P. Casali

Discussion: Can We Make Minimal Common Guidelines for CTOS?

Patient Advocacy Groups

Chair: Ole Nielsen Chairman of the CTOS, Aarhus, Denmark and JY Blay University hosp INSERM U590 Lyon, France

Coffee Break

Molecular Biology for the Patients: How to Define New Targets? How to Predict Outcome?

Chair: P. Reichardt Charit´e;, Berlin, Germany and E. Borden Cleveland Clinic Foundation, Cleveland, OH 44195, USA

[Abstract 445] MUTATED P53 CORRELATES WITH EXTREME SENSITIVITY TO YONDELIS IN LOW PASSAGED CELL LINES EXPLANTED FROM CHEMONAIVE SARCOMA PATIENTS
A. Carnero et al, Madrid, Spain

[Abstract 385] EXPRESSION AND CLINICAL RELEVANCE OF TELOMERE MAINTENANCE MECHANISMS IN LIPOSARCOMA
N. Zaffaroni, Milano, Italy

[Abstract 500] EZRIN EXPRESSION IN OSTEOSARCOMA: COMPARISON OF GENE EXPRESSION ARRAY AND TISSUE MICROARRAY.
T Yan et al, Toronto, Canada

[Abstract 427] ANGIOGENIC PROFILE OF SOFT TISSUE SARCOMAS BASED ON ANALYSIS OF CIRCULATING FACTORS AND MICROARRAY GENE EXPRESSION
S. Yoon et al, Boston, MA

[Abstract 499] TARGETING SOFT TISSUE SARCOMAS BY A SOLUBLE LRP5 DOMINANT-NEGATIVE RECEPTOR.
Y. Guo et al, Los Angeles, CA

Discussion: Identify New Targets and Predict Outcome